Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Alfasigma's Lynavoy (linerixibat) receives CHMP positive opinion for cholestatic pruritus in primary biliary cholangitis following Ph3 success
Small molecule, autoimmune, IBAT inhibitor, primary biliary cholangitis, cholestatic pruritus - Read more

ImmunityBio receives UAE marketing authorization for ANKTIVA (nogapendekin alfa inbakicept) in non-muscle invasive bladder cancer and metastatic non-small cell lung cancer
Protein therapy, cancer, IL-15 cytokine, bladder cancer, non-small cell lung cancer, immunotherapy - Read more

Johnson & Johnson pays Sail Biomedicines $785M upfront, option to acquire for $2.58B in in vivo CAR-T deal
Acquisition option, autoimmune, cell therapy, equity investment, milestone payments - Read more

GSK, Relation Therapeutics deepen AI drug discovery alliance worth up to $110M
Research collaboration, AI/ML, drug discovery, milestone payments, foundation models - Read more

Causaly, Sage partner to integrate full-text scientific literature into AI-powered drug discovery research
Research collaboration, AI/ML, drug discovery, data analytics - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Labcorp posts strong Q2 earnings, raises full-year 2026 revenue guidance to $14.82B
Diagnostics, oncology, revenue impact, financial - Read more

Sanofi raises 2026 outlook after Dupixent quarterly sales surpass €5B ($5.73B) milestone
Monoclonal antibody, atopic dermatitis, financial, revenue impact - Read more

Qureight closes $20M Series B to expand AI imaging portfolio for lung and heart diseases
Imaging CRO, AI/ML platform, cardiovascular, respiratory, biomarker discovery, clinical trial platform - Read more

Trace Biosciences receives undisclosed Series A investment from Axogen, funding Phase II/III clinical trials
Clinical-stage, nerve imaging, surgical visualization, small molecule, medical imaging - Read more

Adjuvia Therapeutics raises $8M Seed funding to advance mitochondrial dysfunction therapeutics pipeline
Rare disease, mitochondrial dysfunction, small molecule, preclinical, neurological - Read more

INOVIO Pharmaceuticals prices $20M public offering, advancing DNA medicines for HPV and cancer
DNA medicines, infectious disease, cancer, HPV, clinical-stage - Read more

Eli Lilly, Resilience commit $750M to boost US diabetes and obesity medicine production
Injectable drug device, diabetes, obesity, manufacturing, major transaction - Read more

Curium advances plans for second cyclotron investment in Romania to expand PET imaging access
Nuclear medicine, diagnostic imaging, operational, investment - Read more

Sanofi CEO pushes stricter Phase 3 go/no-go decisions amid pipeline cuts and €952M ($1.1B) impairment loss
Monoclonal antibody, autoimmune, strategic, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Takeda discontinues (TAK-101) nanoparticle therapy for celiac disease after disappointing Ph2 trial results
Nanoparticle therapy, autoimmune, celiac disease, immune tolerance, gluten, gliadin - Read more

Boston Scientific cuts 2026 revenue guidance to 5-6% growth amid restructuring, Watchman and electrophysiology headwinds
Medical device, cardiovascular, financial, cost reduction, operational - Read more

Daiichi Sankyo's ADC pipeline lags rivals as Enhertu cash flow approaches peak, Jefferies warns
Antibody-drug conjugate, oncology, competitive, financial - Read more

FDA rebukes Viatris for misleading DTC video implying cystic fibrosis inhaler Tobi Podhaler can be used anywhere
Inhaled antibiotic, cystic fibrosis, regulatory, operational - Read more

FDA advisory panel votes against Capricor Therapeutics' (deramiocel) cell therapy for Duchenne muscular dystrophy cardiomyopathy in Ph3
Cell therapy, neuromuscular disease, Duchenne muscular dystrophy, cardiomyopathy, deramiocel - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here